汪凯
学术学位博士生导师
023-68486780
wangkai.virus@qq.com
感染性疾病分子生物学重点实验室
https://www.x-mol.com/groups/cqmu

招生信息

个人简介

汪凯，男，湖北武汉人，研究员，博士生导师。2012年毕业于中国科学院上海巴斯德研究所，获理学博士学位；2015年就职于重庆医科大学，主要从事分子病毒学及肝癌代谢研究；围绕代谢与信号转导的交互调控，旨在揭示代谢重编程在肝癌发生发展中的作用，为肝癌治疗提供新的靶点。重医未来医学青年创新团队“病毒感染与代谢重塑研究团队”负责人，先后主持国家自然科学基金3项、重庆市科委及教委课题4项、重庆医科大学“新冠肺炎”应急课题；作为技术骨干承担国家重点研发计划子任务等。在国内外期刊发表学术论文80余篇，其中以第一/通讯作者（含共同）在Clinical Infectious Diseases、Cell Metabolism、Journal of Clinical Investigation、EMBO J、Cell Research、Nature Communications和STTT等期刊发表SCI论文40余篇（含ESI高被引3篇），总引用3100余次，H指数30。入选Elsevier中国金色开放获取高下载论文学者（2020-2021生命科学领域），获2023川渝科学技术学术大会优秀论文特等奖、重庆市期刊优秀论文一等奖、国家发明专利1项。任中国抗癌协会肿瘤代谢专委会青年委员、重庆抗癌协会化疗专业委员会委员，Advanced Science、Nat Commun等期刊审稿专家。


ORCID: https://orcid.org/0000-0002-0137-1247


工作经历

2024.10 - 至今   重庆医科大学  感染性疾病分子生物学重点实验室   研究员

2020.10 - 2024.09  重庆医科大学  感染性疾病分子生物学重点实验室   副研究员

2019.10 - 2020.09  重庆医科大学  感染性疾病分子生物学重点实验室   副教授

2015.09 - 2019.09  重庆医科大学  基础医学院  病原生物学教研室    讲师

2013.07 - 2015.07  中国科学院   上海生命科学研究院           博士后

2012.05 - 2013.05  中科院上海巴斯德研究所分子病毒与免疫重点实验室  助理研究员


研究方向

(1)分子病毒学——感染与代谢重塑；

(2)代谢重编程调控肝癌发生发展的分子机制研究：关注代谢偶联的蛋白质翻译后修饰（O-GlcNAc糖基化等）。


学术兼职

中国抗癌协会肿瘤代谢专委会青年委员；

重庆抗癌协会化疗专业委员会委员；

Advanced Science、Nat Commun、Clin Transl Med、Genes & Diseases等学术期刊审稿人。


奖励荣誉

2021年 重庆医科大学“优秀科技成果奖”

2021年 爱思唯尔Elsevier“中国金色开放获取高下载论文学者”

2021年 第二十一届重庆市期刊优秀论文 年度优秀论文 一等奖 

2023年 MCE中国生命科学研究促进奖-“秋实”季 卓越贡献奖

2023年 川渝科技学术大会优秀论文 特等奖 (排名第三)

 

科研项目

  1. 国家自然科学基金 (面上项目)，糖异生代谢酶PCK1上调组蛋白H3K9me3修饰抑制肝癌的机制研究

  2. 国家重点研发计划（子任务），代谢重塑在HBV致病性中的作用机制研究

  3. 国家自然科学基金 (面上项目)，PCK1通过降低O-GlcNAc糖基化修饰抑制肝癌转移的机制研究

  4. 国家自然科学基金 (青年基金)，PCK1通过Wnt信号通路抑制肝细胞癌的作用机制研究

  5. 重庆医科大学 未来医学青年创新团队发展支持计划，“病毒感染与代谢重塑研究团队”

  6. 重庆医科大学“新型冠状病毒肺炎”应急专项，SARS-CoV-2假病毒系统的建立及其在抗病毒药物筛选中的应用

  7. 重庆市教委科学技术研究计划（青年项目），PCK1下调β-catenin稳定性抑制肝癌EMT的分子机制研究

  8. 重庆市教育委员会雏鹰计划研究项目，糖异生关键酶抑制肝癌细胞增殖和迁移能力初探

  9. 重庆市自然科学基金（面上项目），PCK1降低Snail1蛋白O-GlcNAc修饰抑制肝癌转移的机制研究 

 

论文情况

 

  1. Z Feng#, J Yin#, Z Zhang#, Z Chen, L Huang*, N Tang*, K Wang*, O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation. Oncogene, 2024. (IF=8) 

  2. D Nie#, X Tang#, H Deng#, X Yang#, J Tao, F Xu, Y Liu, K Wu, K Wang*, Z Mei*, AL Huang*, N Tang*, Metabolic enzyme SLC27A5 regulates PIP4K2A pre-mRNA splicing as a noncanonical mechanism to suppress hepatocellular carcinoma metastasis. Advanced Science, 2024. (IF=15.1)

  3. R Liu#, Y Liu#, W Zhang#, G Zhang#, Z Zhang, L Huang, N Tang*, K Wang*, PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. Genes & Diseases, 2024. (IF= 6.8) 

  4. DA Gong#, P Zhou#, WY Chang#, JY Yang, YL Zhang, AL Huang, N Tang*, K Wang*, SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer. BBA - Molecular Cell Research. 2024. (IF= 5.1) 

  5. P Zhou#, WY Chang#, DA Gong#, J Xia#, W Chen, LY Huang, R Liu, Y Liu, C Chen, K Wang*, N Tang*, AL Huang*, High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate.Cell Metabolism, 2023. (*Co-corresponding author,  IF=29)

  6. Q Ye#, Y Liu#, G Zhang#, H Deng#, X Wang#, L Tuo#, C Chen, X Pan, K Wu, J Fan, Q Pan, K Wang*, AL Huang*, N Tang*, Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice. Nature Communications, 2023. (*Co-corresponding author, IF=17.6)

  7. D Gou#, R Liu#, X Shan#, H Deng#, C Chen#, J Xiang, Y Liu, Q Gao, Z Li, AL Huang*, K Wang*, N Tang*, Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. Journal of Clinical Investigation, 2023. (*Co-corresponding author, IF=19.4)

  8. J Xiang#, C Chen#, R Liu#, D Gou#, L Chang, H Deng, Q Gao, Wanjun Zhang, Lin Tuo, Xuanming Pan, Li Liang, Jie Xia, Luyi Huang, Ke Yao, Bohong Wang, Zeping Hu, Ailong Huang*, Kai Wang*, Ni Tang*, Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. Journal of Clinical Investigation, 2021. (*Co-corresponding author, IF=19.4)

  9. Y Yang#, Y Yan#, J Yin#, N Tang#, K Wang#, L Huang, J Hu, Z Feng, Q Gao, AL Huang*, O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal Transduction and Targeted Therapy, 2023.  (#Co-first author, IF=38.1)

  10. H Luo#, Q Wang#, F Yang#, R Liu#, Q Gao#, B Cheng, X Lin, L Huang, C Chen, J Xiang, K Wang*, B Qin*, N Tang*, Signaling metabolite succinylacetone activates HIF-1α and promotes angiogenesis in GSTZ1-deficient hepatocellular carcinoma. JCI Insight. 2023, (IF= 8) 

  11. P Zhou#, WY Chang#, DA Gong#, LY Huang, R Liu, Y Liu, J Xia, K Wang*, N Tang*, AL Huang*, O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene, 2023.  (*Co-corresponding author, IF=8.8)

  12. R Liu#, D Gou#, J Xiang#, X Pan, Q Gao, P Zhou, Y Liu, J Hu, K Wang*, N Tang*, O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis. Oncogene, 2021. (*Co-corresponding author, IF=8.8) 

  13. Q Gao#, B Cheng#, C Chen#, C Lei#, X Lin, D Nie, J Li, L Huang, XS Li, K Wang*, AL Huang*, N Tang*, Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signaling pathway. Clinical and Translational Medicine, 2022.  (*Co-corresponding author, IF=8.5)

  14. B Mao#, V  Trilling#, K Wang#, D Mennerich, J Hu, Z Zhao, J Zheng, Y Deng, B Katschinski, S Xu, G Zhang, X Cai, Y Hu, J Wang, M Lu, AL Huang*, N Tang*, M Trilling*, Y Lin*，Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. Emerging Microbes & Infections, 2022. (Co-first author, IF=19.5)

  15. J Hu#, XY Wei#, J Xiang#, P Peng, FL Xu, K Wu, FY Luo, AS Jin, L Fang, BZ Liu*, K Wang*, N Tang*, AL Huang*, Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Genes & Diseases, 2022.  (*Co-corresponding author，IF=7.2)

  16. P Peng#, HJ Deng#, J Hu#, XY Wei, JJ Xue, TT Li, L Fang, BZ Liu, AS Jin, FL Xu, K Wu, QX Long, J Chen, K Wang*, N Tang*, AL Huang*, Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine. Cell Discovery, 2021. (*Co-corresponding author, IF= 38.0)

  17. Q Wang#, B Cheng#, Q Xue#, Q Gao, AL Huang*, K Wang*, N Tang*, GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death & Disease, 2021. (*Co-corresponding author, IF=9.6)

  18. Y Liu#, H Deng#, L Liang, G Zhang, J Xia, KY Ding, N Tang*, K Wang*, Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway. Genes & Diseases, 2021. (*Co-corresponding author，IF=7.2)

  19. CL He#, LY Huang#, K Wang#, CJ Gu, J Hu, GJ Zhang, W Xu, YH Xie*, N Tang*, AL Huang*, Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. Signal Transduction and Targeted Therapy, 2021. (#Co-first author, IF=38.1)

  20. J Hu# , P Peng#, K Wang#, L Fang, FY Luo, AS Jin, BZ Liu*, N Tang*, AL Huang*, Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cellular & Molecular Immunology, 2021. (#Co-first author, IF=22)

  21. P Peng#, J Hu#, HJ  Deng, BZ Liu, L Fang, KWang*, N Tang*, AL Huang*, Changes of humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cellular & Molecular Immunology, 2021. (*Co-corresponding author, IF=22.0)

  22. J Hu#, Q Gao#, C He, AL Huang, N Tang*, K Wang*, Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes & Diseases, 2020. (*Corresponding author，IF=7.1)

  23. J Hu#, Q Gao#, Y Yang#, J Xia#, W Zhang, Y Chen, Z Zhou, L Chang, Y Hu, H Zhou, L Liang, X Li, Q Long, K Wang*, AL Huang*, N Tang*, Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation. Theranostics, 2021. (*Co-corresponding author, IF=11.5)

  24. Q Gao#, G Zhang#, Y Zheng#, Y Yang#, C Chen, J Xia, L Liang, C Lei, YHu, XF Cai, W Zhang, H Tang, Y Chen, AL Huang*, K Wang*, N Tang*, SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. Cell Death & Differentiation, 2020.  (*Co-corresponding author, IF=15.8) 

  25. F Yang#, J Li#, H Deng#, Y Wang, C Lei, Q Wang, J Xiang, L Liang, J Xia, X Pan, X Li, Q Long, LChang, P Xu, AL Huang*, K Wang*, N Tang*, GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone. The EMBO Journal, 2019. (*Co-corresponding author, IF=11.5)  

  26. G Zhang#, X Tang#, L Liang#, W Zhang, D Li, X Li, D Zhao, Y Zheng, Y Chen, B Hao, K Wang*, N Tang*, KY Ding*, DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma, Oncogene, 2020. (*Co-corresponding author, IF=9.8)  

  27. J Xiang#, Yu Zhang#, L Tuo, R Liu, D Gou, L Liang, C Chen, J Xia, N Tang, K Wang*, Transcriptomic changes associated with PCK1 overexpression in hepatocellular carcinoma cells detected by RNA-Seq. Genes & Diseases, 2020. (Corresponding author，IF=7.1)

  28. C Lei#, Q Wang, N Tang*, K Wang*, GSTZ1-1 downregulates Wnt/β-catenin signalling in hepatocellular carcinoma cells. FEBS Open Bio, 2020. (IF=2.7)

  29. J Li#, Q Wang#, Y Yang, C Lei, F Yang, L Liang, C Chen, J Xia, K Wang*, N Tang*, GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway. Journal of Experimental & Clinical Cancer Research, 2019. (*Co-corresponding author, IF=11.1)

  30. X Chen#, Y Hu#, W Zhang, K Chen, J Hu, XS Li, L Liang, XF Cai, JL Hu, K Wang*, AL Huang*, N Tang*, Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radical Biology and Medicine, 2019. (*Co-corresponding author, IF=7.3)

  31. L Tuo#, J Xiang#, X Pan#, J Hu, H Tang, L Liang, J Xia, Y Hu, W Zhang, AL Huang*, K Wang*, N Tang*, PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis. Journal of Experimental & Clinical Cancer Research, 2019.(*Co-corresponding author, IF=11.1)  

  32. K Wang#, QX Long#, HJ Deng#, J Hu#, QZ Gao, GJ Zhang, CL He, LY Huang, JL Hu, J Chen#, N Tang#, AL Huang*, Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clinical Infectious Diseases, 2021. (First author, IF=20.9)

  33. K Wang#, W Lv#, J Chen#, S Xie, H Shi, H Hsu, W Yu, K Xu, C Bian, W B Fischer, W Schwarz, L Feng*, B Sun*, PEDV ORF3 encodes an ion channel protein and regulates virus production. FEBS Letters, 2012. 

  34. K Wang#, S Xie, B Sun*. Viral proteins function as ion channels. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2011. 

  35. S Xie#, K Wang#, W Yu, W Lv, K Xu, J Wang, B Ye, W Schwarz, Q Jin*, B Sun*, DIDS blocks a chloride-dependent current that is mediated by the 2B protein of enterovirus 71, Cell Research, 2011. (#Co-first author)

  36. Q Gao#, K Wang#, K Chen, L Liang, Y Zheng, Y Zhang, J Xiang, N Tang *, HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. Cancer Science, 2017. 

  37. R Zhang#, K Wang#, W Lv#, W Yu, S Xie, K Xu, W Schwarz, SD Xiong*, B Sun*, The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2014. 

  38. R Zhang#, K Wang, X Ping, W Yu, Z Qian, SD Xiong*, B Sun*, The ns12. 9 accessory protein of human coronavirus OC43 is a viroporin involved in virion morphogenesis and pathogenesis. Journal of Virology, 2015.

  39. S Schwarz#, K Wang, W Yu, B Sun, W Schwarz*, Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Research, 2011.

  40. 向进，庹琳，高庆祝，杨翼，梁利，夏杰，唐霓，汪凯*. PCK1影响肝癌细胞迁移能力的研究. 重庆医科大学学报, 2018.

  41. 潘璇明，张桂冀，陈雪梅，梁利，唐霓，汪凯*. 果糖-1，6-二磷酸酶1抑制肝癌细胞株HepG2的自噬及增殖. 中华肝脏病杂志, 2019.

  42. 龚德敖，唐霓，汪凯*. 斑点型锌指结构蛋白在肿瘤中的作用. 生命的化学，2022.

  43. 杨佳瑶，唐霓，汪凯*.己糖胺生物合成途径代谢酶与OGT介导的O-GlcNAc修饰在肿瘤中的研究进展.重庆医科大学学报,2023.

 

知识产权

  1. 汪凯，唐霓，聂丹，唐鑫. 一种肝癌组织中 PIP4K2A 剪接变异体的应用，专利号 ZL202310059552.9

  2. 汪凯，唐霓，庹琳，向进，潘璇明. 6-重氮-5-氧代-L-正亮氨酸在制备预防或治疗肝癌药物中的应用，申请号 CN201811063773.9

  3. 唐霓，汪凯，黄爱龙，夏杰 等. 氨基氧乙酸在制备治疗肝细胞肝癌的药物中的应用，专利号 ZL201910064794.0

  4. 唐霓，汪凯，高庆祝，陈昶 等. 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用，专利号 ZL202210860675.8

  5. 黄露义，唐霓，汪凯，黄爱龙，何长龙. 双苄四氢异喹啉衍生物在制备抗冠状病毒药物中的应用, 专利号 ZL202011375253.9

  6. 黄露义，唐霓，汪凯，黄爱龙，杨泱. N-磺酰基杂环衍生物及其制药用途, 专利号 ZL202011640906.1

  7. 黄露义，唐霓，汪凯，黄爱龙，单晓群. 一种新型O-GlcNAc转移酶抑制剂及其用途  申请号 CN202211102591.4

  8. 夏杰，黄爱龙，刘迪娜，唐霓，汪凯，蔡莹 等. 一种肝纤维化或肝硬化的诊断试剂盒， 申请号 CN201911315897.6

  9. 林永，毛彬力，黄爱龙，唐霓，汪凯，赵珍玉 等. 二叶草素在制备抗新型冠状病毒的药物中的用途, 申请号CN202110092946.5

 

研究方向

肝癌代谢重编程；分子病毒学